M
M. von Bergwelt-Baildon
Researcher at University of Cologne
Publications - 30
Citations - 379
M. von Bergwelt-Baildon is an academic researcher from University of Cologne. The author has contributed to research in topics: Antigen & Cytotoxic T cell. The author has an hindex of 11, co-authored 30 publications receiving 312 citations. Previous affiliations of M. von Bergwelt-Baildon include Harvard University.
Papers
More filters
Journal ArticleDOI
Management of sepsis in neutropenic cancer patients: 2018 guidelines from the Infectious Diseases Working Party (AGIHO) and Intensive Care Working Party (iCHOP) of the German Society of Hematology and Medical Oncology (DGHO)
Matthias Kochanek,Enrico Schalk,M. von Bergwelt-Baildon,Gernot Beutel,Dieter Buchheidt,M. Hentrich,Larissa Henze,Michael G. Kiehl,Tobias Liebregts,M. von Lilienfeld-Toal,Annika Y. Classen,Sibylle C. Mellinghoff,Olaf Penack,C. Piepel,Boris Böll +14 more
TL;DR: The aim of the current guideline is to give evidence-based recommendations for hematologists, oncologists, and intensive care physicians on how to manage adult patients with neutropenia and sepsis.
Journal ArticleDOI
CD40-activated B cells can be generated in high number and purity in cancer patients: analysis of immunogenicity and homing potential.
Eisei Kondo,Luise Gryschok,Nela Klein-Gonzalez,S. Rademacher,Martin R. Weihrauch,Tanja M. Liebig,Alexander Shimabukuro-Vornhagen,M. Kochanek,Andreas Draube,M. von Bergwelt-Baildon +9 more
TL;DR: It is shown that proliferation of B cells from cancer patients is equivalent to that observed in healthy donors, and CD40‐B cells can be expanded in virtually unlimited numbers at high purity and full function concerning antigen‐presentation and migratory properties.
Journal ArticleDOI
CD40 activation: potential for specific immunotherapy in B-CLL
TL;DR: Biology and potential therapeutic applications of the CD40-system in CLL are discussed and theCD40-CD40L interaction has been shown to significantly increase antigen presentation in normal and malignant B-cells.
Journal ArticleDOI
Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients.
Britta Maecker,Britta Maecker,M. von Bergwelt-Baildon,M. von Bergwelt-Baildon,Karen S. Anderson,Robert H. Vonderheide,KC Anderson,Lee M. Nadler,Joachim L. Schultze,Joachim L. Schultze +9 more
TL;DR: Examining whether patients with MM have an endogenous pre‐existing immune response against recently identified epitopes from hTERT and CYP1B1 suggests strategies targeting these antigens may have to utilize techniques to induce T cell responses from a naive precursor frequency.
Journal ArticleDOI
Linking Genomics to Immunotherapy by Reverse Immunology - ‘Immunomics’ in the New Millennium
Britta Maecker,M. von Bergwelt-Baildon,Karen S. Anderson,Robert H. Vonderheide,Joachim L. Schultze +4 more
TL;DR: This review will focus on the process from in silico analysis of expression databases and screening of potential candidate genes by bioinformatics to the in vitro and in vivo analysis to determine the immunogenicity of candidate tumor antigens.